Literature DB >> 30259643

Understanding the influence of individual variables contributing to multivariate outliers in assessments of data quality.

Richard C Zink1, Laura Castro-Schilo2, Jianfeng Ding2.   

Abstract

Mahalanobis distance is often recommended to identify patients or clinical sites that are considered unusual in clinical trials. Patients extreme in one or more covariates may be considered outliers in that they reside some distance from the multivariate mean, which can be thought of as the center of the data cloud. Less often discussed, patients whose data are believed to be "too good to be true" are located near the centroid as inliers. In order to efficiently investigate these anomalies for potential lapses in data quality, it is important to understand how the individual variables contribute to each multivariate outlier. There is a lack of literature describing a reasonable workflow for identification of outliers and their subsequent investigation to understand how each variable contributes to an observation being considered extreme. We describe how to identify multivariate inliers and outliers, classify outliers according to varying levels of severity, and summarize the contributions of variables using principal components in a manner that is accessible to a wide audience with straightforward interpretation. We illustrate how numerous data visualizations, including Pareto plots, can facilitate further review even in studies containing numerous observations and variables. We illustrate these methodologies using data from a multicenter clinical trial.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Mahalanobis distance; data visualization; good clinical practice; principal components; risk-based approaches; statistical monitoring

Mesh:

Year:  2018        PMID: 30259643     DOI: 10.1002/pst.1903

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  1 in total

1.  Bayesian central statistical monitoring using finite mixture models in multicenter clinical trials.

Authors:  Tomoyoshi Hatayama; Seiichi Yasui
Journal:  Contemp Clin Trials Commun       Date:  2020-04-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.